Case-Based Roundtable
General Dermatology
Eczema
Chronic Hand Eczema
Chronic Spontaneous Urticaria
Alopecia
Aesthetics
Vitiligo
COVID-19
Actinic Keratosis
Precision Medicine and Biologics
Rare Disease
Wound Care
Rosacea
Psoriasis
Psoriatic Arthritis
Atopic Dermatitis
Melasma
NP and PA
Skin Cancer
Hidradenitis Suppurativa
Drug Watch
Pigmentary Disorders
Acne
Pediatric Dermatology
Practice Management
Prurigo Nodularis
Buy-and-Bill

Article

August 1, 2006

Melanoma drug 'fast-tracked'

West Haven, Conn. - The kidney cancer drug Nexavar has been granted fast track designation by the Food and Drug Administration for treatment of advanced melanoma, manufacturer Bayer Pharmaceuticals announced.

West Haven, Conn. - The kidney cancer drug Nexavar has been granted fast track designation by the Food and Drug Administration for treatment of advanced melanoma, manufacturer Bayer Pharmaceuticals announced.

Nexavar was approved last year for treatment of renal cell carcinoma.

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.

Subscribe Now!

Melanoma drug 'fast-tracked'

Newsletter